JP6446657B2 - 脂質の代謝をモニタリングする方法 - Google Patents
脂質の代謝をモニタリングする方法 Download PDFInfo
- Publication number
- JP6446657B2 JP6446657B2 JP2015121273A JP2015121273A JP6446657B2 JP 6446657 B2 JP6446657 B2 JP 6446657B2 JP 2015121273 A JP2015121273 A JP 2015121273A JP 2015121273 A JP2015121273 A JP 2015121273A JP 6446657 B2 JP6446657 B2 JP 6446657B2
- Authority
- JP
- Japan
- Prior art keywords
- acetone
- breath
- breath sample
- volatile organic
- isotope ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000037356 lipid metabolism Effects 0.000 title claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 75
- 229910052799 carbon Inorganic materials 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 74
- 239000012855 volatile organic compound Substances 0.000 claims description 48
- 238000002470 solid-phase micro-extraction Methods 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 27
- 238000012544 monitoring process Methods 0.000 claims description 27
- 238000003860 storage Methods 0.000 claims description 16
- 239000002274 desiccant Substances 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 10
- 238000005070 sampling Methods 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 255
- 239000000523 sample Substances 0.000 description 91
- 206010012601 diabetes mellitus Diseases 0.000 description 36
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 31
- 239000000835 fiber Substances 0.000 description 25
- 238000005259 measurement Methods 0.000 description 23
- 235000014113 dietary fatty acids Nutrition 0.000 description 22
- 229930195729 fatty acid Natural products 0.000 description 22
- 239000000194 fatty acid Substances 0.000 description 22
- 150000004665 fatty acids Chemical class 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 17
- 238000007664 blowing Methods 0.000 description 13
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 238000002485 combustion reaction Methods 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 238000011088 calibration curve Methods 0.000 description 5
- 238000009841 combustion method Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000002307 isotope ratio mass spectrometry Methods 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 239000010453 quartz Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000006371 metabolic abnormality Effects 0.000 description 4
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000025938 carbohydrate utilization Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000004433 infrared transmission spectrum Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Description
図1は、本発明の呼気試料採取容器の一例を示す概略部分縦断面図である。図1の呼気試料採取容器9は、呼気を吹き入れるための注入口1と、吹き入れられた呼気を呼気試料として貯蔵するための貯蔵部5と、貯蔵された呼気試料を排出するための排出口3とを具備し、注入口1を開閉するための注入口開閉弁2と、排出口3を開閉するための排出口開閉弁4とを更に具備するものである。
呼気の採取は、下記のような手法で行うことができる。
図2は、本発明の呼気試料採取容器に好適に用いられるSPME機器等を示す説明図である。図2において、(a)はSPME機器の概略側面図であり、(b)は(a)のSMPE機器のニードル部の拡大図であり、(c)は、呼気試料中のアセトン(揮発性有機化合物の典型例)を、ニードル部に吸着する様子を示す図である。
以下、本発明の呼気試料採取容器を、呼気試料中に含まれる揮発性有機化合物の天然の安定炭素同位体比(13C/12C)を分析する方法および脂質の代謝をモニタリングする方法に適用する際の原理を説明する。
呼気試料中に含まれる揮発性有機化合物の天然の安定炭素同位体比(13C/12C)を分析する方法は、呼気試料中に含まれる揮発性有機化合物の天然の安定炭素同位体比(13C/12C)を測定する工程を含み、天然の安定炭素同位体比(13C/12C)を測定する際に、上述の呼気試料採取容器を用いる。
本発明の脂質の代謝をモニタリングする方法は、(a)呼気試料中に含まれる揮発性有機化合物を、呼気試料から濃縮抽出する工程と、(b)濃縮抽出された揮発性有機化合物の天然の安定炭素同位体比(13C/12C)を測定する工程と、を含み、揮発性有機化合物の天然の安定炭素同位体比(13C/12C)の減少が生体内における脂質の代謝の亢進を示し、揮発性有機化合物を、呼気試料から濃縮抽出する手段が、上述の呼気試料採取容器を含む。
図1に示すような呼気試料採取容器を準備した。容器の容量は、目的に応じて最適の容量のものを使えばよいが、本実施例では100mLのものを用いた。また、乾燥剤には、硫酸ナトリウム1gを用いた。
呼気試料からアセトンを抽出する方法として、固相マイクロ抽出(SPME)法を用いた。SPME機器のファイバー部のファイバー表面に吸着材をコーティングした(図2(a)、(b))。本実施例ではコーティング剤として、アセトンを選択的に抽出することの出来るCarboxen(商標)/PDMSを使用した。なお、未使用時、ファイバー部はホルダー部内に格納されており、抽出時にファイバーを暴露させることで、目的成分を吸着させた(図2(c))。
アセトンの天然の安定炭素同位体比(13C/12C)は、ガスクロマトグラフィー−燃焼−同位体比質量分析計(GC−C−IRMS)を用いて測定した。アセトン濃度の測定は同じGC−C−IRMSのGCを用いて測定した。
本実施例ではSPME法により、呼気試料からアセトンを抽出している。この方法におけるアセトンは、ファイバーへの吸着を経てGCに打ち込まれて測定されるため、その間での同位体分別が起こり、測定で得られる天然の安定炭素同位体比は真値とは異なる可能性が考えられる。そこで、封緘燃焼法を用いてアセトンの天然の安定炭素同位体比の真値を求めた。SPME法と封緘燃焼法のそれぞれで得られた天然の安定炭素同位体比を用いて作成した検量線から、SPME法で得られる天然の安定炭素同位体比の補正を行った。
δ13C (‰)={(13C/12C)試料/(13C/12C)標準−1}×1000 (1)
・空腹→糖質不足→脂質(脂肪酸)利用率増大→アセトン量増大、13C/12C減少
・食事摂取→糖質補充→脂質(脂肪酸)利用率低下→アセトン量減少、13C/12C増加
2 注入口開閉弁
3 排出口
4 排出口開閉弁
5 貯蔵部
6 抽出口
7 セプタム
8 乾燥剤
9 呼気試料採取容器
10 SPME機器
11 ホルダー部
12 ニードル部
Claims (4)
- 脂質の代謝をモニタリングする方法であって、
(a)呼気試料中に含まれる揮発性有機化合物を、前記呼気試料から濃縮抽出する工程と、
(b)濃縮抽出された前記揮発性有機化合物の天然の安定炭素同位体比( 13 C/ 12 C)を測定する工程と、を含み、
前記揮発性有機化合物の天然の安定炭素同位体比( 13 C/ 12 C)の減少が生体内における脂質の代謝の亢進を示し、
前記揮発性有機化合物を、前記呼気試料から濃縮抽出する手段が、呼気試料採取容器を含み、
前記呼気試料採取容器は、
呼気を吹き入れるための注入口と、吹き入れられた前記呼気を呼気試料として貯蔵するための貯蔵部と、貯蔵された前記呼気試料を排出するための排出口とを具備し、
前記注入口を開閉するための注入口開閉弁と、前記排出口を開閉するための排出口開閉弁とを更に具備することを特徴とする、方法。 - 前記呼気試料採取容器は、前記呼気試料から揮発した揮発性有機化合物を固相マイクロ抽出(SPME)するための抽出口を具備することを特徴とする、請求項1に記載の方法。
- 前記呼気試料採取容器は、前記呼気試料から揮発した揮発性有機化合物を抽出するための抽出口を具備し、前記抽出口が、樹脂から成るセプタムにより封止されていることを特徴とする、請求項1または2に記載の方法。
- 前記呼気試料採取容器は、前記貯蔵部の内部に乾燥剤を具備することを特徴とする、請求項1〜3のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015121273A JP6446657B2 (ja) | 2015-06-16 | 2015-06-16 | 脂質の代謝をモニタリングする方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015121273A JP6446657B2 (ja) | 2015-06-16 | 2015-06-16 | 脂質の代謝をモニタリングする方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017009288A JP2017009288A (ja) | 2017-01-12 |
JP6446657B2 true JP6446657B2 (ja) | 2019-01-09 |
Family
ID=57761414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015121273A Active JP6446657B2 (ja) | 2015-06-16 | 2015-06-16 | 脂質の代謝をモニタリングする方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6446657B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7361517B2 (ja) * | 2018-07-17 | 2023-10-16 | 大阪瓦斯株式会社 | 指標値決定システム、ミトコンドリア活性評価システム、指標値決定方法及びミトコンドリア活性評価方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07198562A (ja) * | 1993-12-28 | 1995-08-01 | Nippon Sanso Kk | ガス採取方法 |
JP3170432B2 (ja) * | 1995-05-15 | 2001-05-28 | 日本無線株式会社 | 呼気採取バック |
EP1031033B1 (fr) * | 1997-11-15 | 2005-10-05 | Brechbühler AG | Procede et appareillage pour la mesure des volatils globaux |
JP2002055103A (ja) * | 2000-08-12 | 2002-02-20 | Shino Test Corp | 終末呼気採取用呼気バッグ及び呼気試験 |
JP2003315219A (ja) * | 2002-04-22 | 2003-11-06 | Asahi Kasei Corp | 揮発性物質の放散速度スクリーニング装置 |
EP2909329B1 (en) * | 2012-10-19 | 2017-04-12 | Avisa Pharma Inc. | Methods for detecting bacterial infections |
-
2015
- 2015-06-16 JP JP2015121273A patent/JP6446657B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017009288A (ja) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
King et al. | Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study | |
Turner et al. | Breath acetone concentration decreases with blood glucose concentration in type I diabetes mellitus patients during hypoglycaemic clamps | |
Buszewski et al. | Human exhaled air analytics: biomarkers of diseases | |
Smith et al. | Can volatile compounds in exhaled breath be used to monitor control in diabetes mellitus? | |
Risby et al. | Current status of clinical breath analysis | |
US7104963B2 (en) | Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath | |
Schmidt et al. | Ammonia in breath and emitted from skin | |
Turner et al. | A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS | |
Davies et al. | Breath analysis of ammonia, volatile organic compounds and deuterated water vapor in chronic kidney disease and during dialysis | |
Storer et al. | Measurement of breath acetone concentrations by selected ion flow tube mass spectrometry in type 2 diabetes | |
US6461870B2 (en) | 13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control | |
JP6146872B2 (ja) | アセトン中の天然の安定炭素同位体比の分析方法、並びに脂質代謝のモニタリング方法 | |
Nose et al. | Identification of gas emanated from human skin: methane, ethylene, and ethane | |
CN111103423B (zh) | 一种检测肠道菌群代谢气体的呼气试验方法 | |
EP1610681B1 (en) | Method and apparatus for monitoring intravenous (iv) drug concentration using exhaled breath | |
Beauchamp et al. | Breath sampling and standardization | |
JP6446657B2 (ja) | 脂質の代謝をモニタリングする方法 | |
Zhou et al. | A non-invasive method for the detection of glucose in human exhaled breath by condensation collection coupled with ion chromatography | |
Fink et al. | Indole as a new tentative marker in exhaled breath for non-invasive blood glucose monitoring of diabetic subjects | |
Badjagbo | Exhaled breath analysis for early cancer detection: principle and progress in direct mass spectrometry techniques | |
JP6471983B2 (ja) | 呼気試料中イソプレンの天然の安定炭素同位体比(13c/12c)を分析する方法、および血糖値のモニタリング方法 | |
JPH0647047A (ja) | 臨床用呼気検査方法及び装置 | |
Španˇel et al. | Recent SIFT-MS studies of volatile compounds in physiology, medicine and cell biology | |
KR20190088662A (ko) | 날숨 가스 분석을 위한 표준 시료 및 분석 방법 | |
EP4085832B1 (en) | Non-invasive determination of blood glucose levels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170530 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180410 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181030 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6446657 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |